美托洛尔联合曲美他嗪治疗冠心病心力衰竭临床疗效分析

目的观察美托洛尔与曲美他嗪联合治疗冠心病心力衰竭的临床疗效，探讨其临床价值。方法将给与常规治疗的48例冠心病并心力衰竭患者视为对照组，采用美托洛尔联合曲美他嗪治疗的48例冠心病并心力衰竭患者视为观察组，观察两组患者临床疗效及心功能改善情况。结果观察组总有效率为95．83％，明显高于对照组的83．33％（P〈0．05）；观察组治疗6个月后LVEF明显高于对照组（P〈0．05），LVESD及LVEDD均明显低于对照组（P〈0．05）。结论美托洛尔联合曲美他嗪治疗冠心病心力衰竭具有疗效好、见效快、药效持久等优点，可作为目前治疗冠心病心力衰竭的一种较佳治疗方案。

The clinical efficacy of metoprolol combined with trimetazidine for cardiac failure due to coronary heart disease

Objective To investigate the clinical efficacy of combination therapy with metoprolol and trimetazidine in the treatment of cardiac failure due to coronary heart disease （CHD）. Methods 96 patients with cardiac failure due to CHD divided study group and control group, 48 for each group. The control group received routine comprehensive treatment, while the study group received metoprolol combined with trimetazidine. The clinical efficacy and improvement in cardiac function were observed in the two groups, Results The total effec- tiveness rate was significantly higher in the study group than in the control group （95.83% vs. 83.33%, P〈0.05 ）. Six months after treatment, LVEF was significantly greater while LVESD and LVEDD were markedly smaller in the study group than in the control group （P〈0.05 for all comparisons）. Conclhusiom Combination therapy with metoprolol and trimetazidine is efficacious and has a rapid onset of action and a longer-lasting action. It can be used as an ideal therapeutic regimen for cardiac failure due to coronary heart disease.